Severity, Criticality, and Fatality of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Beta Variant.

Laith JAbu-Raddad; Hiam Chemaitelly ORCID logo; Houssein HAyoub; Hadi MYassine; Fatiha MBenslimane; Hebah AAl Khatib; PatrickTang; Mohammad RHasan; PeterCoyle; SawsanAlMukdad; +14 more... ZainaAl Kanaani; EinasAl Kuwari; AndrewJeremijenko; Anvar HassanKaleeckal; Ali NizarLatif; Riyazuddin MohammadShaik; Hanan FAbdul Rahim; Gheyath KNasrallah; Mohamed GhaithAl Kuwari; Adeel AButt; Hamad EidAl Romaihi; Mohamed HAl-Thani; AbdullatifAl Khal; RobertoBertollini; (2021) Severity, Criticality, and Fatality of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Beta Variant. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 75 (1). e1188-e1191. ISSN 1058-4838 DOI: 10.1093/cid/ciab909
Copy

Beta (B.1.351)-variant coronavirus disease 2019 (COVID-19) disease was investigated in Qatar. Compared with the Alpha (B.1.1.7) variant, odds (95% confidence interval) of progressing to severe disease, critical disease, and COVID-19-related death were 1.24-fold (1.11-1.39), 1.49-fold (1.13-1.97), and 1.57-fold (1.03-2.43) higher, respectively, for the Beta variant.



picture_as_pdf
ciab909.pdf
subject
Published Version
Available under Creative Commons: 3.0

View Download

Explore Further

Read more research from the creator(s):

Find work associated with the faculties and division(s):

Find work associated with the research centre(s):

Find work from this publication: